Compare Halozyme Therapeutics Inc. Common Stock (HALO) vs iShares Broad USD Investment Grade Corporate Bond (USIG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Halozyme Therapeutics Inc. Common Stock vs iShares Broad USD Investment Grade Corporate Bond — how do they compare? Halozyme Therapeutics Inc. Common Stock trades at $110.42 (market cap $12.58B), while iShares Broad USD Investment Grade Corporate Bond trades at $48.77 (market cap $17.53B). The key difference: iShares Broad USD Investment Grade Corporate Bond is the larger of the two by market cap, and Halozyme Therapeutics Inc. Common Stock is trading nearer its 52-week high, iShares Broad USD Investment Grade Corporate Bond nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Halozyme Therapeutics Inc. Common Stock for 1 Days and iShares Broad USD Investment Grade Corporate Bond for 44 Days on average.
| HALO | USIG | |
|---|---|---|
Market Cap | $12.58B | $17.53B |
Volume | 2,179,278 | 4,695,583 |
Sector | Health | Fixed Income |
52-Week High | $115.22 | $52.69 |
52-Week Low | $61.63 | $48.54 |
Typical Hold Time | 1 Days | 44 Days |
Enterprise Value | $14.49B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
USIG trades at $48.77 with minimal daily movement (+0.18%). Technical indicators show a bearish trend with moving averages signaling caution, though oscillators remain neutral. The ETF maintains regular dividend distributions with recent payouts of $0.20-$0.21 per share. Institutional activity includes Blue Edge Capital establishing a new $21.9 million position and Bank of New York Mellon increasing its stake by 0.9% in Q2 2026.
The investment grade corporate bond ETF faces headwinds from rising interest rate concerns, though institutional accumulation suggests confidence in long-term credit quality. Key risks include credit spread volatility and macroeconomic sensitivity, while the steady dividend stream provides income stability for conservative investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Halozyme Therapeutics Inc. Common Stock
Halozyme Therapeutics develops drug-delivery technologies for biopharmaceutical companies. Its ENHANZE technology uses the rHuPH20 enzyme to support subcutaneous delivery of co-administered medicines.
Read more on HALO →About iShares Broad USD Investment Grade Corporate Bond
USIG is a low-cost ETF providing broad exposure to over 11,000 U.S. investment-grade corporate bonds. It tracks the ICE BofA US Corporate Index, featuring high-quality debt from 2026 leaders like Citigroup, Bank of America, and Oracle.
Read more on USIG →
